ATE168694T1 - Triantennar cluster glykoside, ihre herstellung und verwendung - Google Patents

Triantennar cluster glykoside, ihre herstellung und verwendung

Info

Publication number
ATE168694T1
ATE168694T1 AT93921124T AT93921124T ATE168694T1 AT E168694 T1 ATE168694 T1 AT E168694T1 AT 93921124 T AT93921124 T AT 93921124T AT 93921124 T AT93921124 T AT 93921124T AT E168694 T1 ATE168694 T1 AT E168694T1
Authority
AT
Austria
Prior art keywords
pct
cluster
date
triantennar
production
Prior art date
Application number
AT93921124T
Other languages
English (en)
Inventor
Ericus Anna Leonardus Biessen
Berkel Theodorus Josephus Van
Boom Jacobus Hubertus Van
Original Assignee
Univ Leiden
Nl Hartstichting
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leiden, Nl Hartstichting filed Critical Univ Leiden
Application granted granted Critical
Publication of ATE168694T1 publication Critical patent/ATE168694T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C07H15/08—Polyoxyalkylene derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0088—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing unsubstituted amino radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
AT93921124T 1992-08-11 1993-08-11 Triantennar cluster glykoside, ihre herstellung und verwendung ATE168694T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NL9201440A NL9201440A (nl) 1992-08-11 1992-08-11 Triantennaire clusterglycosiden, hun bereiding en toepassing.

Publications (1)

Publication Number Publication Date
ATE168694T1 true ATE168694T1 (de) 1998-08-15

Family

ID=19861173

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93921124T ATE168694T1 (de) 1992-08-11 1993-08-11 Triantennar cluster glykoside, ihre herstellung und verwendung

Country Status (10)

Country Link
US (1) US5885968A (de)
EP (1) EP0655070B1 (de)
JP (1) JPH08502726A (de)
AT (1) ATE168694T1 (de)
AU (1) AU674160B2 (de)
DE (1) DE69319912T2 (de)
DK (1) DK0655070T3 (de)
ES (1) ES2122041T3 (de)
NL (1) NL9201440A (de)
WO (1) WO1994004545A1 (de)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2216844A1 (en) * 1995-03-31 1996-10-03 Drug Delivery System Institute, Ltd. Amidite derivatives and oligonucleotide derivatives
US5855911A (en) 1995-08-29 1999-01-05 Board Of Regents, The University Of Texas System Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
DE19631189A1 (de) * 1996-08-02 1998-02-05 Max Delbrueck Centrum Neuartige kationische Amphiphile für den liposomalen Gentransfer
US6977244B2 (en) 1996-10-04 2005-12-20 Board Of Regents, The University Of Texas Systems Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
US7704962B1 (en) 1997-10-03 2010-04-27 Board Of Regents, The University Of Texas System Small oligonucleotides with anti-tumor activity
US7285288B1 (en) 1997-10-03 2007-10-23 Board Of Regents, The University Of Texas System Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
GB2372502B (en) * 2000-12-12 2004-10-13 Imperial College Carbohydrate compounds containing cholesterol and their use
US9657294B2 (en) 2002-02-20 2017-05-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US9181551B2 (en) 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
PL2539451T3 (pl) 2010-02-24 2016-08-31 Arrowhead Res Corporation Kompozycje do ukierunkowanego dostarczania siRNA
US9260471B2 (en) 2010-10-29 2016-02-16 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
BR112013013434A2 (pt) 2010-12-17 2016-08-16 Arrowhead Res Corp metade que tem por alvo modulador fármaco cinético em cacho de galactose para sirna
US8501930B2 (en) 2010-12-17 2013-08-06 Arrowhead Madison Inc. Peptide-based in vivo siRNA delivery system
CA2842039A1 (en) 2011-08-26 2013-03-07 Arrowhead Research Corporation Poly(vinyl ester) polymers for in vivo nucleic acid delivery
US20140100178A1 (en) * 2012-10-04 2014-04-10 Aslam Ansari Composition and methods for site-specific drug delivery to treat malaria and other liver diseases
JP2016503300A (ja) 2012-11-15 2016-02-04 ロシュ・イノベーション・センター・コペンハーゲン・アクティーゼルスカブＲｏｃｈｅ Ｉｎｎｏｖａｔｉｏｎ Ｃｅｎｔｅｒ Ｃｏｐｅｎｈａｇｅｎ Ａ／Ｓ 抗ＡｐｏＢアンチセンス複合体化合物
WO2014118272A1 (en) 2013-01-30 2014-08-07 Santaris Pharma A/S Antimir-122 oligonucleotide carbohydrate conjugates
CN104955952A (zh) 2013-01-30 2015-09-30 弗·哈夫曼-拉罗切有限公司 Lna寡核苷酸碳水化合物缀合物
DK3013959T3 (da) 2013-06-27 2020-02-17 Roche Innovation Ct Copenhagen As Antisense-oligomerer og konjugater målrettet pcsk9
GB201408623D0 (en) 2014-05-15 2014-07-02 Santaris Pharma As Oligomers and oligomer conjugates
TW201620526A (zh) 2014-06-17 2016-06-16 愛羅海德研究公司 用於抑制α－１抗胰蛋白酶基因表現之組合物及方法
JP2018509913A (ja) 2015-03-17 2018-04-12 アローヘッド ファーマシューティカルズ インコーポレイテッド 第ｘｉｉ因子の遺伝子発現を阻害するための組成物と方法
KR20180038465A (ko) 2015-08-07 2018-04-16 애로우헤드 파마슈티컬스 인코포레이티드 Ｂ형 간염 바이러스 감염에 대한 ｒｎａｉ 치료법
JOP20210043A1 (ar) 2015-10-01 2017-06-16 Arrowhead Pharmaceuticals Inc تراكيب وأساليب لتثبيط تعبير جيني للـ lpa
CN113797348A (zh) 2016-03-07 2021-12-17 箭头药业股份有限公司 用于治疗性化合物的靶向配体
AU2017235278C1 (en) 2016-03-14 2022-03-10 F. Hoffmann-La Roche Ag Oligonucleotides for reduction of PD-L1 expression
EP3228326A1 (de) 2016-04-05 2017-10-11 Silence Therapeutics GmbH Nucleinsäure verbunden mit einem dreiwertigen glykokonjugat
MA45496A (fr) 2016-06-17 2019-04-24 Hoffmann La Roche Molécules d'acide nucléique pour la réduction de l'arnm de padd5 ou pad7 pour le traitement d'une infection par l'hépatite b
JOP20170161A1 (ar) 2016-08-04 2019-01-30 Arrowhead Pharmaceuticals Inc عوامل RNAi للعدوى بفيروس التهاب الكبد ب
AU2017320582B2 (en) * 2016-09-02 2023-11-16 Arrowhead Pharmaceuticals, Inc Targeting ligands
JOP20180003B1 (ar) 2017-01-10 2022-09-15 Arrowhead Pharmaceuticals Inc عوامل RNAi ألفا-1 مضادة للتريبسين (AAT)، وتركيبات تتضمن عوامل AAT RNAi، وطرق الاستخدام
WO2018185240A1 (en) 2017-04-05 2018-10-11 Silence Therapeutics Gmbh Products and compositions
EP3385381A1 (de) 2017-04-05 2018-10-10 Silence Therapeutics GmbH Produkte und zusammensetzungen
EP3385272A1 (de) 2017-04-05 2018-10-10 Silence Therapeutics GmbH Weitere neuartige oligonukleotid-ligand-konjugate
EP3550022A1 (de) 2018-04-05 2019-10-09 Silence Therapeutics GmbH Produkte und zusammensetzungen
WO2018185253A1 (en) 2017-04-05 2018-10-11 Silence Therapeutics Gmbh Ligand modified double-stranded nucleic acids
WO2018185239A1 (en) 2017-04-05 2018-10-11 Silence Therapeutics Gmbh Products and compositions
EP4219713A3 (de) 2017-04-05 2023-08-16 Silence Therapeutics GmbH Produkte und zusammensetzungen
EP3483269A1 (de) 2017-11-13 2019-05-15 Silence Therapeutics GmbH Produkte und zusammensetzungen
WO2018185252A1 (en) 2017-04-05 2018-10-11 Silence Therapeutics Gmbh Nucleic acid conjugates
EP3385380A1 (de) 2017-04-05 2018-10-10 Silence Therapeutics GmbH Produkte und zusammensetzungen
US10597657B2 (en) 2017-09-11 2020-03-24 Arrowhead Pharmaceuticals, Inc. RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3)
PE20201287A1 (es) 2017-09-14 2020-11-24 Arrowhead Pharmaceuticals Inc Agentes de iarn y composiciones para inhibir la expresion de la angiopoyetina tipo 3 (angptl3) y metodos de uso
US10953034B2 (en) 2017-10-16 2021-03-23 Hoffmann-La Roche Inc. Nucleic acid molecule for reduction of PAPD5 and PAPD7 mRNA for treating hepatitis B infection
CN111212909A (zh) 2017-10-17 2020-05-29 箭头药业股份有限公司 用于抑制去唾液酸糖蛋白受体1的表达的RNAi试剂和组合物
PL3710586T3 (pl) 2017-11-13 2023-03-20 Silence Therapeutics Gmbh Kwasy nukleinowe do hamowania ekspresji LPA w komórce
CN111527206A (zh) 2017-11-13 2020-08-11 赛伦斯治疗有限责任公司 用于抑制靶标基因表达的包含二硫代磷酸酯键的核酸
EP3483270A1 (de) 2017-11-13 2019-05-15 Silence Therapeutics GmbH Produkte und zusammensetzungen
WO2019092282A1 (en) 2017-11-13 2019-05-16 Silence Therapeutics Gmbh Nucleic acids for inhibiting expression of aldh2 in a cell
EP3550021A1 (de) 2018-04-05 2019-10-09 Silence Therapeutics GmbH Produkte und zusammensetzungen für die inhibierung der expression eines zielgens
US11560563B2 (en) 2018-04-05 2023-01-24 Silence Therapeutics Gmbh SiRNAs with vinylphosphonate at the 5′ end of the antisense strand
CR20210179A (es) 2018-07-03 2022-05-23 Hoffmann La Roche OLIGONUCLEÓTIDOS PARA MODULAR LA EXPRESIÓN DE TAU (Divisional 2021-0058)
EP3598995A1 (de) 2018-07-26 2020-01-29 Silence Therapeutics GmbH Produkte und zusammensetzungen
WO2020043750A1 (en) 2018-08-28 2020-03-05 Roche Innovation Center Copenhagen A/S Neoantigen engineering using splice modulating compounds
SI3880818T1 (sl) 2018-11-13 2023-01-31 Silence Therapeutics Gmbh Nukleinske kisline za inhibiranje izražanja LPA v celici
EP3730617A1 (de) 2019-04-26 2020-10-28 Silence Therapeutics GmbH Nukleinsäure zur hemmung der expression von c3 in einer zelle
CA3119234A1 (en) 2018-11-23 2020-05-28 Silence Therapeutics Gmbh Nucleic acids for inhibiting expression of c3 in a cell
EP3920884A1 (de) 2019-02-07 2021-12-15 Arrowhead Pharmaceuticals, Inc. Rnai-mittel gegen infektion mit dem hepatitis-b-virus
JP7503072B2 (ja) 2019-02-26 2024-06-19 ロシュ イノベーション センター コペンハーゲン エーエス オリゴヌクレオチドの製剤化方法
AU2020269323A1 (en) 2019-05-07 2021-10-28 Silence Therapeutics Gmbh Nucleic acids for inhibiting expression of PROS1 in a cell
TW202113081A (zh) 2019-06-06 2021-04-01 美商愛羅海德製藥公司 用於治療α-1抗胰蛋白酶缺乏症(AATD)的方法
EP3986562A1 (de) 2019-06-18 2022-04-27 Janssen Sciences Ireland Unlimited Company Kombination von hepatitis-b-virus(hbv)-impfstoffen und auf hbv abzielender rnai
KR20220047865A (ko) 2019-08-27 2022-04-19 사일런스 테라퓨틱스 게엠베하 세포에서 c3의 발현을 억제하기 위한 핵산
EP4081639A1 (de) 2019-12-24 2022-11-02 F. Hoffmann-La Roche AG Pharmazeutische kombination eines therapeutischen oligonucleotids gegen hbv und eines tlr7-agonisten zur behandlung von hbv
MX2022007909A (es) 2019-12-24 2022-07-21 Hoffmann La Roche Combinacion farmaceutica de agentes antivirales que actuan sobre hbv y/o un inmunomodulador para el tratamiento de hbv.
UY39138A (es) 2020-03-26 2021-09-30 Arrowhead Pharmaceuticals Inc Agentes de arni para inhibir la expresión de pnpla3, composiciones farmacéuticas de esta, y métodos de uso
WO2021239825A1 (en) 2020-05-27 2021-12-02 Silence Therapeutics Gmbh Nucleic acids for inhibiting expression of cnnm4 in a cell
US20230348905A1 (en) 2020-09-15 2023-11-02 Arrowhead Pharmaceuticals, Inc. Methods for the reduction of z-aat protein levels
TW202237840A (zh) 2020-11-04 2022-10-01 瑞士伯恩大學 用於在細胞中抑制pros1之表現的核酸
WO2022184852A1 (en) 2021-03-03 2022-09-09 Silence Therapeutics Gmbh Conjugated nucleic acids comprising a phosphorodithioate for inhibiting gene expression in a cell
WO2022223557A1 (en) 2021-04-20 2022-10-27 Silence Therapeutics Gmbh Nucleic acids for inhibiting expression of xdh in a cell
MX2023012834A (es) 2021-04-27 2023-11-08 Silence Therapeutics Gmbh Inhibidor de la matriptasa-2 para el tratamiento de trastornos mieloproliferativos.
US11549112B1 (en) 2021-06-21 2023-01-10 Arrowhead Pharmaceuticals, Inc. RNAi agents for inhibiting expression of xanthine dehydrogenase (XDH), pharmaceutical compositions thereof, and methods of use
WO2023031359A1 (en) 2021-09-02 2023-03-09 Silence Therapeutics Gmbh Nucleic acids for inhibiting expression of complement factor b (cfb) in a cell
WO2023233290A1 (en) 2022-05-31 2023-12-07 Janssen Sciences Ireland Unlimited Company Rnai agents targeting pd-l1
WO2024126687A1 (en) 2022-12-16 2024-06-20 Silence Therapeutics Gmbh Nucleic acids conjugated to an albumin binding moiety

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US751219A (en) * 1904-02-02 Leaf-turner
US4751219A (en) * 1985-02-05 1988-06-14 Nederlandse Centrale Organisatie Voor Toegepast-Natuur-Wetenschappelijk Onderzoek Synthetic glycolipides, a process for the preparation thereof and several uses for these synthetic glycolipides
FR2637185A1 (fr) * 1988-10-05 1990-04-06 Ire Celltarg Sa Vecteurs synthetiques de faible poids moleculaire, utilisation en therapie ciblee et en imagerie medicale et procedes de preparation
NZ264340A (en) * 1993-09-01 1995-04-27 Akzo Nobel Nv Bisconjugate comprising two saccharides and a spacer, use in pharmaceutical compositions

Also Published As

Publication number Publication date
EP0655070A1 (de) 1995-05-31
AU674160B2 (en) 1996-12-12
AU4835593A (en) 1994-03-15
EP0655070B1 (de) 1998-07-22
DK0655070T3 (da) 1999-04-26
JPH08502726A (ja) 1996-03-26
US5885968A (en) 1999-03-23
DE69319912T2 (de) 1999-04-15
DE69319912D1 (de) 1998-08-27
ES2122041T3 (es) 1998-12-16
WO1994004545A1 (en) 1994-03-03
NL9201440A (nl) 1994-03-01

Similar Documents

Publication Publication Date Title
ATE168694T1 (de) Triantennar cluster glykoside, ihre herstellung und verwendung
DK0695171T3 (da) Lyosfærer indeholdende gonadotropin
IT1276071B1 (it) Compositi ad attivita' anti-infiammatoria
FI964789A (fi) Elastaasin pefluorialkyyliketoni-inhibiittoreita ja menetelmiä niiden valmistamiseksi
NO2012003I1 (no) 4-aminopyridin eller et derivat derav
DK1042340T3 (da) 6-O-alkylerythromycinoxim-B
TR199900501T2 (xx) Benzamin t�revleri ve bunlar�n ila� olarak kullan�m�.
BG102250A (en) The use of marigold-extracted glycosides for the treatment of psoriasis
ATE71113T1 (de) Antibiotikum a 40926 mannosyl aglycon.
ATE184912T1 (de) Kontinuierliche zellinie sowie impfstoff gegen geflügelinfektion mit kokkidien
ATE68001T1 (de) 11-beta-nitrat-substituierte estrane.
SE8702188L (sv) Farmaceutiska kompositioner
DE68918944D1 (de) Künstliche rezeptor-analoge.
MX9301235A (es) DERIVADOS 1,4-DIOXINO(2,3-B)PIRIDINA. á
NO304754B1 (no) Modulkanalsystem med et tverrsnitt med avrundete hjoerner
BG102404A (en) The application of flupirtin for the prevention and treatment of diseases related to impairement of the haematopoeic cellular system
BR9913107A (pt) Derivados de benzoilguanidina, com propriedades vantajosas, processos para sua preparação e seu uso na produção de medicamentos
DE59607683D1 (de) Neue borneolderivate, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung
DE69323191D1 (de) Wasserlösliche retinoide
ATE174509T1 (de) Metabolisierbarer plasmaersatz
Highsmith et al. Clinical microbiology newsletter.
SU1513867A1 (ru) 2,2'-азобис{2-циано-5-[6-или(4-метил-3)(2,3-эпоксипропоксикарбамино)гексил - или (фенил)аминокарбокси]пентаны} в качестве промежуточных продуктов для получения эпоксидных олигомеров
KR910009280A (ko) 원발성 흉막암 치료용 제약 조성물의 제조에 있어서 감마 인터페론 활성을 갖는 폴리펩티드의 용도
IT8620514V0 (it) Struttura di cannula vaginale monouso, per l'applicazione di pomate, medicamenti semidensi e simili.
RU2076528C1 (ru) Штамм вируса омской геморрагической лихорадки для приготовления диагностических препаратов

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee